JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

Search

PROCEPT BioRobotics Corp

Avatud

SektorTervishoid

36.16 -2.16

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

35.86

Max

37.22

Põhinäitajad

By Trading Economics

Sissetulek

5.2M

-20M

Müük

10M

79M

Kasumimarginaal

-24.727

Töötajad

756

EBITDA

-1.3M

-24M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+70.95% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-813M

1.9B

Eelmine avamishind

38.32

Eelmine sulgemishind

36.16

Uudiste sentiment

By Acuity

50%

50%

154 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

PROCEPT BioRobotics Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. okt 2025, 23:50 UTC

Kuumad aktsiad

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28. okt 2025, 23:25 UTC

Tulu

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28. okt 2025, 23:18 UTC

Tulu

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28. okt 2025, 22:20 UTC

Tulu

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28. okt 2025, 22:13 UTC

Tulu

Wal-Mart de Mexico Net Profit Falls in 3Q

28. okt 2025, 21:38 UTC

Tulu

Correction to Visa Sales Jump Article

28. okt 2025, 21:17 UTC

Tulu

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28. okt 2025, 21:07 UTC

Tulu

Visa Sales Jump as Consumers Keep Spending -- Update

28. okt 2025, 21:02 UTC

Tulu

Mondelez Tempers Outlook as Costs Rise

28. okt 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28. okt 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28. okt 2025, 23:02 UTC

Tulu

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28. okt 2025, 23:01 UTC

Tulu

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28. okt 2025, 22:46 UTC

Tulu

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28. okt 2025, 22:45 UTC

Tulu

SK Hynix 3Q Net KRW12.6T >000660.SE

28. okt 2025, 22:44 UTC

Tulu

SK Hynix 3Q Rev KRW24.44T >000660.SE

28. okt 2025, 22:43 UTC

Tulu

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28. okt 2025, 22:42 UTC

Tulu

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28. okt 2025, 22:40 UTC

Tulu

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28. okt 2025, 22:40 UTC

Tulu

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28. okt 2025, 22:20 UTC

Tulu

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28. okt 2025, 22:02 UTC

Tulu

Review & Preview: Earnings Extravaganza -- Barrons.com

28. okt 2025, 21:42 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

28. okt 2025, 21:42 UTC

Market Talk
Tulu

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28. okt 2025, 21:20 UTC

Tulu

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28. okt 2025, 21:19 UTC

Tulu

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28. okt 2025, 21:18 UTC

Tulu

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Võrdlus sarnastega

Hinnamuutus

PROCEPT BioRobotics Corp Prognoos

Hinnasiht

By TipRanks

70.95% tõus

12 kuu keskmine prognoos

Keskmine 62.14 USD  70.95%

Kõrge 85 USD

Madal 50 USD

Põhineb 9 Wall Streeti analüütiku instrumendi PROCEPT BioRobotics Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

8

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

52.655 / 56.31Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

154 / 373 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
help-icon Live chat